Jiří Špaček
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiří Špaček has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ondřej Kubeček
Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital in Hradec Králové, Charles University, Sokolská 581, 50005 Hradec Králové, Czech Republic
4 shared publications - Stanislav Filip
Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czechia
4 shared publications - Milan Bláha
4th Department of Internal Medicine-Haematology, Faculty Hospital in Hradec Králové, 50005 Hradec Králové, Czech Republic
3 shared publications - Miriam Lánská
4th Department of Internal Medicine-Haematology, Faculty Hospital in Hradec Králové, 50005 Hradec Králové, Czech Republic
2 shared publications Alena Kubečková
Department of Obstetrics and Gynecology, Faculty of Medicine and University Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic
1 shared publication- Dominik Habes
Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Noninvasive assessment of oxidative stress in pelvic organ prolapse: a feasibility study
Pelvic organ prolapse (POP) is increasingly relevant in aging populations. Oxidative stress (OS) may weaken pelvic support structures, but previous studies relied on invasive tissue sampling, limiting longitudinal use. This study evaluated whether OS markers can be detected non-invasively in vaginal fluid and whether they correlate with POP severity. We prospectively enrolled 160 women with POP between February 2021 and June 2023. Vaginal fluid samples were collected, and three OS markers: 8-hydroxy-2′-deoxyguanosine (8-OHdG), 4-hydroxynonenal (HNE), and advanced glycation end products (AGE) were quantified using commercial ELISA kits. POP severity was assessed by POP-Q and ultrasound parameters. 8-OHdG was consistently detectable and significantly elevated in advanced POP compared to early stages (p = 0.001), showing a modest positive correlation with prolapse severity (ρ = 0.24, p < 0.001). Regression analysis confirmed 8-OHdG as an independent predictor of prolapse severity (R2 = 0.964). AGE levels did not differ significantly between groups, and HNE values were below detection thresholds in most samples. No associations were found between OS markers and age, BMI, or menopause duration. Non-invasive assessment of oxidative stress in vaginal fluid is feasible. Elevated 8-OHdG correlates with POP severity, supporting its potential as a biomarker for disease monitoring and future translational research.
- 8 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessNoninvasive assessment of oxidative stress in pelvic organ prolapse: a feasibility study
Pelvic organ prolapse (POP) is increasingly relevant in aging populations. Oxidative stress (OS) may weaken pelvic support structures, but previous studies relied on invasive tissue sampling, limiting longitudinal use. This study evaluated whether OS markers can be detected non-invasively in vaginal fluid and whether they correlate with POP severity. We prospectively enrolled 160 women with POP between February 2021 and June 2023. Vaginal fluid samples were collected, and three OS markers: 8-hydroxy-2′-deoxyguanosine (8-OHdG), 4-hydroxynonenal (HNE), and advanced glycation end products (AGE) were quantified using commercial ELISA kits. POP severity was assessed by POP-Q and ultrasound parameters. 8-OHdG was consistently detectable and significantly elevated in advanced POP compared to early stages (p = 0.001), showing a modest positive correlation with prolapse severity (ρ = 0.24, p < 0.001). Regression analysis confirmed 8-OHdG as an independent predictor of prolapse severity (R2 = 0.964). AGE levels did not differ significantly between groups, and HNE values were below detection thresholds in most samples. No associations were found between OS markers and age, BMI, or menopause duration. Non-invasive assessment of oxidative stress in vaginal fluid is feasible. Elevated 8-OHdG correlates with POP severity, supporting its potential as a biomarker for disease monitoring and future translational research.
- Open Access
- 17 November 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (11) , 1103
Erratum: Filip, S.; et al. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. Pharmaceutics 2020, 12, 940
The following correction has been made to this paper
- 17 November 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (11) , 1103
Open AccessErratum: Filip, S.; et al. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. Pharmaceutics 2020, 12, 940
The following correction has been made to this paper
- Open Access
- 30 September 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10) , 940
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years
Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.
- 30 September 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10) , 940
Open AccessTherapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years
Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.
- 15 June 2020
- Published by Care Comm in Perspectives in Surgery
- Vol. 99 (6) , 271-276
Hand-assisted laparoscopic nephrectomy in morbidly obese patients
Introduction: Prevalence of obesity is 30 % in the Czech Republic and is expected to increase further in the future. This disease complicates surgical procedures but also the postoperative period. The aim of our paper is to present the surgical technique called hand-assisted laparoscopic nephrectomy (HALS), used in surgical management of kidney cancer in morbid obese patients with BMI >40 kg/m2. Methods: The basic cohort of seven patients with BMI >40 undergoing HALS nephrectomy was retrospectively evaluated. Demographic data were analyzed (age, gender, body weight, height, BMI and comorbidities). The perioperative course (surgery time, blood loss, ICU time, hospital stay and early complications), tumor characteristics (histology, TNM classification, tumor size, removed kidney size) and postoperative follow-up were evaluated. Results: The patient age was 38−67 years; the cohort included 2 females and 5 males, the body weight was 117−155 kg and the BMI was 40.3−501 kg/m2. Surgery time was 73−98 minutes, blood loss was 20−450 ml, and hospital stay was 5−7 days; incisional hernia occurred in one patient. Kidney cancer was confirmed in all cases, 48–110 mm in diameter, and the largest removed specimen size was 210×140×130 mm. One patient died just 9 months after the surgery because of metastatic disease; the tumor-free period in the other patients currently varies between 1 and 5 years. Conclusion: HALS nephrectomy seems to be a suitable and safe surgical technique in complicated patients like these morbid obese patients. HALS nephrectomy provides acceptable surgical and oncological results.
- 15 June 2020
- Published by Care Comm in Perspectives in Surgery
- Vol. 99 (6) , 271-276
Hand-assisted laparoscopic nephrectomy in morbidly obese patients
Introduction: Prevalence of obesity is 30 % in the Czech Republic and is expected to increase further in the future. This disease complicates surgical procedures but also the postoperative period. The aim of our paper is to present the surgical technique called hand-assisted laparoscopic nephrectomy (HALS), used in surgical management of kidney cancer in morbid obese patients with BMI >40 kg/m2. Methods: The basic cohort of seven patients with BMI >40 undergoing HALS nephrectomy was retrospectively evaluated. Demographic data were analyzed (age, gender, body weight, height, BMI and comorbidities). The perioperative course (surgery time, blood loss, ICU time, hospital stay and early complications), tumor characteristics (histology, TNM classification, tumor size, removed kidney size) and postoperative follow-up were evaluated. Results: The patient age was 38−67 years; the cohort included 2 females and 5 males, the body weight was 117−155 kg and the BMI was 40.3−501 kg/m2. Surgery time was 73−98 minutes, blood loss was 20−450 ml, and hospital stay was 5−7 days; incisional hernia occurred in one patient. Kidney cancer was confirmed in all cases, 48–110 mm in diameter, and the largest removed specimen size was 210×140×130 mm. One patient died just 9 months after the surgery because of metastatic disease; the tumor-free period in the other patients currently varies between 1 and 5 years. Conclusion: HALS nephrectomy seems to be a suitable and safe surgical technique in complicated patients like these morbid obese patients. HALS nephrectomy provides acceptable surgical and oncological results.
- 14 November 2019
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 85 (2) , 353-365
Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer
The present study evaluates the safety and efficacy of double-plasma filtration (PF) to remove the exceeding pegylated liposomal doxorubicin (PLD) in circulation, thus reducing mucocutaneous toxicity.
- 14 November 2019
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 85 (2) , 353-365
Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer
The present study evaluates the safety and efficacy of double-plasma filtration (PF) to remove the exceeding pegylated liposomal doxorubicin (PLD) in circulation, thus reducing mucocutaneous toxicity.
- Top Cited PapersOpen Access
- 1 June 2017
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 34 (5) , 295-307
The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review
Secondary tumors of the ovary account for 10–25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer. The correct diagnosis of secondary ovarian tumors may be challenging as they are not infrequently misdiagnosed as primary ovarian cancer, particularly in the case of mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, may suggest the primary tumor site. Despite extensive study, some cases remain equivocal even after assessing a broad spectrum of antigens. Therefore, gene expression profiling represents an approach able to further discriminate equivocal findings, and one that has been proven effective in determining the origin of cancer of unknown primary site. The available data concerning secondary ovarian tumors is rather limited owing to the relative heterogeneity of this group and the practical absence of any prospective trials. However, several intriguing questions are encountered in daily practice, including rational diagnostic workup, the role of cytoreductive surgery, and consequent adjuvant chemotherapy. This review seeks to address these issues comprehensively and summarize current knowledge on the epidemiology, pathogenesis, and management of secondary ovarian tumors, including further discussion on the different pathways of metastatisation, metastatic organotropism, and their possible molecular mechanisms.
- 1 June 2017
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 34 (5) , 295-307
Top Cited PapersOpen AccessThe pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review
Secondary tumors of the ovary account for 10–25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer. The correct diagnosis of secondary ovarian tumors may be challenging as they are not infrequently misdiagnosed as primary ovarian cancer, particularly in the case of mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, may suggest the primary tumor site. Despite extensive study, some cases remain equivocal even after assessing a broad spectrum of antigens. Therefore, gene expression profiling represents an approach able to further discriminate equivocal findings, and one that has been proven effective in determining the origin of cancer of unknown primary site. The available data concerning secondary ovarian tumors is rather limited owing to the relative heterogeneity of this group and the practical absence of any prospective trials. However, several intriguing questions are encountered in daily practice, including rational diagnostic workup, the role of cytoreductive surgery, and consequent adjuvant chemotherapy. This review seeks to address these issues comprehensively and summarize current knowledge on the epidemiology, pathogenesis, and management of secondary ovarian tumors, including further discussion on the different pathways of metastatisation, metastatic organotropism, and their possible molecular mechanisms.